Sign up to save your podcasts
Or
Share The Real Problem With Modern Healthcare
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Real Problem With Modern Healthcare
“You don’t need to leave the U.S. to get real stem cell therapy.” – Seth Berge
In this episode of Compound Wisdom, Steve Sood sits down with Seth Berge, founder of Regenerative Revival, to unpack what’s really holding back regenerative medicine—and why the problem isn’t the science, but the system delivering it.
Seth shares his unconventional path from high-ticket direct-to-consumer sales into the stem cell space, revealing how real demand and promising outcomes were being undermined by friction, poor communication, and broken follow-up models. Together, they explore how education-first selling, concierge care, and compliant systems can dramatically improve patient outcomes while still allowing the business to scale.
The conversation dives deep into stem cell myths, why leaving the U.S. for treatment is often unnecessary, and how regulation—when done right—can actually become a competitive advantage. Seth also explains the growing role of IV stem cells and exosomes in wellness, longevity, and inflammation support, along with where the regenerative health industry is heading next.
Takeaways- Friction in healthcare kills trust, outcomes, and conversion
- Great medicine often fails because of broken delivery systems
- Education-first models outperform traditional clinic selling
- Stem cells can be explained without medical jargon
- You don’t need to leave the U.S. for legitimate stem cell access
- FDA “non-approval” does not mean illegal or ineffective
- Cultured and expanded cells overseas carry unknown risks
- IV stem cells and exosomes are emerging wellness tools
- Concierge, mobile care improves patient experience and scale
- Regulation can eliminate bad actors and reward compliant operators
Chapters
00:01 Friction Kills Conversion
02:07 Seth’s Entry Into Stem Cells Through Sales
04:13 Full Rooms, Zero Conversions
05:42 Removing Friction From the Model
06:22 Why Dinner Seminars Still Work
09:12 Stem Cells Explained Simply
11:14 The Overseas Stem Cell Myth
13:47 Cultured Cells vs Non-Manipulated Tissue
15:42 Marketing Limits in the U.S.
17:01 IV Stem Cells and Exosomes
19:31 How Often to Use Stem Cells for Optimization
20:24 Pricing, Access, and Market Maturity
22:30 Helping Med Spas Enter the Space
25:16 Addressing Skepticism and Credibility
28:07 Concierge, At-Home Treatment
30:10 Regulation and the Future of Regenerative Medicine
34:19 Biggest Risks in Telehealth
35:59 Learning From Competitors
View all episodes
By Dante McClain“You don’t need to leave the U.S. to get real stem cell therapy.” – Seth Berge
In this episode of Compound Wisdom, Steve Sood sits down with Seth Berge, founder of Regenerative Revival, to unpack what’s really holding back regenerative medicine—and why the problem isn’t the science, but the system delivering it.
Seth shares his unconventional path from high-ticket direct-to-consumer sales into the stem cell space, revealing how real demand and promising outcomes were being undermined by friction, poor communication, and broken follow-up models. Together, they explore how education-first selling, concierge care, and compliant systems can dramatically improve patient outcomes while still allowing the business to scale.
The conversation dives deep into stem cell myths, why leaving the U.S. for treatment is often unnecessary, and how regulation—when done right—can actually become a competitive advantage. Seth also explains the growing role of IV stem cells and exosomes in wellness, longevity, and inflammation support, along with where the regenerative health industry is heading next.
Takeaways- Friction in healthcare kills trust, outcomes, and conversion
- Great medicine often fails because of broken delivery systems
- Education-first models outperform traditional clinic selling
- Stem cells can be explained without medical jargon
- You don’t need to leave the U.S. for legitimate stem cell access
- FDA “non-approval” does not mean illegal or ineffective
- Cultured and expanded cells overseas carry unknown risks
- IV stem cells and exosomes are emerging wellness tools
- Concierge, mobile care improves patient experience and scale
- Regulation can eliminate bad actors and reward compliant operators
Chapters
00:01 Friction Kills Conversion
02:07 Seth’s Entry Into Stem Cells Through Sales
04:13 Full Rooms, Zero Conversions
05:42 Removing Friction From the Model
06:22 Why Dinner Seminars Still Work
09:12 Stem Cells Explained Simply
11:14 The Overseas Stem Cell Myth
13:47 Cultured Cells vs Non-Manipulated Tissue
15:42 Marketing Limits in the U.S.
17:01 IV Stem Cells and Exosomes
19:31 How Often to Use Stem Cells for Optimization
20:24 Pricing, Access, and Market Maturity
22:30 Helping Med Spas Enter the Space
25:16 Addressing Skepticism and Credibility
28:07 Concierge, At-Home Treatment
30:10 Regulation and the Future of Regenerative Medicine
34:19 Biggest Risks in Telehealth
35:59 Learning From Competitors